Axon Enterprise, Inc (NASDAQ:AXON) Shares Sold by Wealth Enhancement Advisory Services LLC

Wealth Enhancement Advisory Services LLC lowered its position in Axon Enterprise, Inc (NASDAQ:AXON - Free Report) by 24.4% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 12,803 shares of the biotechnology company's stock after selling 4,129 shares during the period. Wealth Enhancement Advisory Services LLC's holdings in Axon Enterprise were worth $6,734,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently added to or reduced their stakes in the company. CX Institutional purchased a new stake in Axon Enterprise in the 1st quarter worth approximately $115,000. Xponance Inc. boosted its holdings in shares of Axon Enterprise by 3.5% in the 4th quarter. Xponance Inc. now owns 16,469 shares of the biotechnology company's stock valued at $9,788,000 after purchasing an additional 560 shares during the last quarter. Brighton Jones LLC acquired a new position in shares of Axon Enterprise in the 4th quarter valued at $480,000. Fjarde AP Fonden Fourth Swedish National Pension Fund boosted its holdings in shares of Axon Enterprise by 16.2% in the 4th quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund now owns 12,200 shares of the biotechnology company's stock valued at $7,251,000 after purchasing an additional 1,700 shares during the last quarter. Finally, NorthRock Partners LLC acquired a new position in shares of Axon Enterprise in the 4th quarter valued at $555,000. 79.08% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on AXON shares. Needham & Company LLC lifted their price target on shares of Axon Enterprise from $600.00 to $750.00 and gave the company a "buy" rating in a report on Thursday, May 8th. Bank of America lifted their target price on shares of Axon Enterprise from $750.00 to $895.00 and gave the company a "buy" rating in a report on Wednesday, June 4th. The Goldman Sachs Group boosted their price objective on shares of Axon Enterprise from $730.00 to $830.00 and gave the stock a "buy" rating in a report on Wednesday, May 14th. Barclays boosted their target price on shares of Axon Enterprise from $726.00 to $735.00 and gave the stock an "overweight" rating in a research report on Friday, May 9th. Finally, Craig Hallum lowered shares of Axon Enterprise from a "buy" rating to a "cautious" rating in a research note on Monday, March 10th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and ten have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $699.55.

Axon Enterprise Stock Up 1.4%

AXON stock opened at $794.25 on Wednesday. The firm has a market capitalization of $61.83 billion, a P/E ratio of 191.85, a P/E/G ratio of 90.16 and a beta of 1.29. The company has a debt-to-equity ratio of 0.68, a current ratio of 2.83 and a quick ratio of 2.62. The company's 50 day simple moving average is $700.64 and its 200-day simple moving average is $627.10. Axon Enterprise, Inc has a 52-week low of $279.02 and a 52-week high of $806.64.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last posted its earnings results on Wednesday, May 7th. The biotechnology company reported $1.41 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.34 by $0.07. The business had revenue of $603.63 million for the quarter, compared to analyst estimates of $585.67 million. Axon Enterprise had a net margin of 14.86% and a return on equity of 5.81%. Axon Enterprise's revenue was up 31.3% compared to the same quarter last year. During the same period last year, the business posted $1.15 EPS. As a group, equities research analysts anticipate that Axon Enterprise, Inc will post 5.8 EPS for the current year.

Insider Buying and Selling

In related news, CAO Jennifer H. Mak sold 75 shares of the company's stock in a transaction dated Friday, June 13th. The shares were sold at an average price of $771.81, for a total transaction of $57,885.75. Following the completion of the sale, the chief accounting officer now owns 15,240 shares of the company's stock, valued at $11,762,384.40. This represents a 0.49% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, President Joshua Isner sold 9,000 shares of the company's stock in a transaction dated Monday, May 12th. The stock was sold at an average price of $683.31, for a total transaction of $6,149,790.00. Following the sale, the president now directly owns 308,714 shares of the company's stock, valued at $210,947,363.34. This represents a 2.83% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 44,642 shares of company stock valued at $30,500,428 in the last 90 days. 5.70% of the stock is owned by insiders.

Axon Enterprise Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.